WEST CHESTER, Ohio, Feb 05, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (NASDAQ:ATRC), a medical device company and a leader in
cardiac surgical ablation products, will release its financial results
for the fourth quarter and year ended December 31, 2009 on Thursday,
February 18, 2010.
AtriCure will host a conference call at 10:00 a.m. Eastern Time on
Thursday, February 18, 2010 to discuss its fourth quarter and full year
2009 financial results. A live web cast of the conference call will be
available online from the investor relations page of AtriCure's
corporate web site at www.atricure.com.
Pre-registration is available and recommended for this call at the
following URL:
https://www.theconferencingservice.com/prereg/key.process?key=PFRRMKUCP
You may also access this call through an operator by calling
888-713-4199 for domestic callers and 617-213-4861 for international
callers at least 15 minutes prior to the call start time using
reservation code 71939893.
The webcast will be available on AtriCure's web site and a telephonic
replay of the call will also be available through March 18, 2010. The
replay dial-in numbers are 888-286-8010 for domestic callers and
617-801-6888 for international callers. The reservation code is 52921254.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart,
tissue. Medical journals have described the adoption by leading
cardiothoracic surgeons of the AtriCure Isolator(R) bipolar
ablation system as a treatment alternative during open-heart surgical
procedures to create lesions in cardiac tissue to block the abnormal
electrical impulses that cause atrial fibrillation, or AF, a rapid,
irregular quivering of the upper chambers of the heart. Additionally,
medical journals and leading cardiothoracic surgeons have described the
AtriCure Isolatorsystem as a promising treatment alternative
for patients who may be candidates for sole-therapy minimally invasive
procedures. AF affects more than 5.5 million people worldwide and
predisposes them to a five-fold increased risk of stroke. The FDA has
cleared the AtriCure Isolator system and AtriCure's multifunctional pen
and CoolrailTM linear ablation device, for the ablation, or
destruction, of cardiac tissue during surgical procedures. Additionally,
the FDA has cleared AtriCure's multifunctional pen for temporary pacing,
sensing, stimulating and recording during the evaluation of cardiac
arrhythmias and AtriCure's Cryo1 system for the cryosurgical treatment
of cardiac arrhythmias. To date, the FDA has not cleared or approved
AtriCure's products for the treatment of AF.
SOURCE: AtriCure, Inc.
AtriCure, Inc.
Vice President and Chief Financial Officer
Julie A. Piton, 513-755-4561
jpiton@atricure.com
